INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 12, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 17,274 | $320.48 | 1,089,060 |
| Jul 10, 2014 |
Ten Percent Owner
Trans History: 555
|
Ten Percent Owner | Form 4 | Open market or private purchase of non-derivative or derivative security | 17,286 | $314.58 | 21,775,741 |
| Jun 28, 2006 |
Director
Trans History: 742
|
Director | Form 4 | Bona fide gift | 17,309 | -- | 373,176 |
| Jul 10, 2014 |
Ten Percent Owner
Trans History: 555
|
Ten Percent Owner | Form 4 | Open market or private purchase of non-derivative or derivative security | 17,347 | $308.55 | 21,623,060 |
| Dec 16, 2010 |
Director
Trans History: 742
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 17,384 | $32.04 | 153,128 |
| May 14, 2010 |
Director
Trans History: 742
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 17,400 | $27.19 | 531,351 |
| Jan 05, 2005 |
VP, Gen Counsel & Secretary
Trans History: 117
|
VP, Gen Counsel & Secretary | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,482 | -- | 19,148 |
| Dec 09, 2020 |
EVP Research and Development
Trans History: 660
|
EVP Research and Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,500 | -- | 17,500 |
| Jul 26, 2012 |
Director
Trans History: 368
|
Director | Form 5 | Bona fide gift | 17,500 | -- | 27,500 |
| Jul 26, 2012 |
Director
Trans History: 368
|
Director | Form 5 | Bona fide gift | 17,500 | -- | 27,500 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.